<author><surname>Levin</surname> <given-names>B.</given-names> </author><title>Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable</title><source>Cancer</source><year>2002</year><volume>95</volume><fpage>1618</fpage><lpage>1628</lpage>
<author><surname>Ladabaum</surname> <given-names>U.</given-names> </author><author><surname>Song</surname> <given-names>K.</given-names> </author><title>Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand</title><source>Gastroenterology</source><year>2005</year><volume>129</volume><fpage>1151</fpage><lpage>1162</lpage>
<author><surname>Hill</surname> <given-names>L.B.</given-names> </author><author><surname>O'Connell</surname> <given-names>J.B.</given-names> </author><author><surname>Ko</surname> <given-names>C.Y.</given-names> </author><title>Colorectal cancer: epidemiology and health services research</title><source>Surg. Oncol. Clin. N. Am.</source><year>2006</year><volume>15</volume><fpage>21</fpage><lpage>37</lpage>
<author><surname>Ries</surname> <given-names>L.A.G.</given-names> </author><author><surname>Eisner</surname> <given-names>M.P.</given-names> </author><author><surname>Kosary</surname> <given-names>C.L.</given-names> </author><source>SEER Cancer Statistics Review</source><year>(1975-2002)</year><publisher>National Cancer Institute</publisher>
American Cancer Society<source>Colorectal cancer facts &amp; figures</source><year>2007</year><issue>special edition</issue><other>Atlanta, Georgia</other><publisher>American Cancer Society</publisher>
<author><surname>Anthony</surname> <given-names>T.</given-names> </author><title>Colorectal cancer follow-up in 2005</title><source>Surg. Oncol. Clin. N. Am.</source><year>(2006)</year><volume>viii</volume><issue>15</issue><fpage>175</fpage><lpage>193</lpage>
<author><surname>Graffner</surname> <given-names>H.</given-names> </author><author><surname>Hultberg</surname> <given-names>B.</given-names> </author><author><surname>Johansson</surname> <given-names>B.</given-names> </author><author><surname>Moller</surname> <given-names>T.</given-names> </author><author><surname>Petersson</surname> <given-names>B.G.</given-names> </author><title>Detection of recurrent cancer of the colon and rectum</title><source>J. Surg. Oncol.</source><year>1985</year><volume>28</volume><fpage>156</fpage><lpage>159</lpage>
<author><surname>Renehan</surname> <given-names>A.G.</given-names> </author><author><surname>Egger</surname> <given-names>M.</given-names> </author><author><surname>Saunders</surname> <given-names>M.P.</given-names> </author><author><surname>O'Dwyer</surname> <given-names>S.T.</given-names> </author><title>Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis</title><source>Br. J. Cancer</source><year>2005</year><volume>92</volume><fpage>430</fpage><lpage>433</lpage>
<author><surname>Secco</surname> <given-names>G.B.</given-names> </author><title>Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial</title><source>Eur. J. Surg. Oncol.</source><year>2002</year><volume>28</volume><fpage>418</fpage><lpage>423</lpage>
<author><surname>Pietra</surname> <given-names>N.</given-names> </author><title>Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study</title><source>Dis. Colon. Rectum.</source><year>1998</year><volume>41</volume><fpage>1127</fpage><lpage>1133</lpage>
<author><surname>Kitagawa</surname> <given-names>Y.</given-names> </author><title>Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues</title><source>Histopathology</source><year>2002</year><volume>40</volume><fpage>472</fpage><lpage>479</lpage>
<author><surname>Maestranzi</surname> <given-names>S.</given-names> </author><author><surname>Przemioslo</surname> <given-names>R.</given-names> </author><author><surname>Mitchell</surname> <given-names>H.</given-names> </author><author><surname>Sherwood</surname> <given-names>R.A.</given-names> </author><title>The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA</title><source>Ann. Clin. Biochem.</source><year>1998</year><volume>35</volume><issue>(Pt 1)</issue><fpage>99</fpage><lpage>103</lpage>
<author><surname>Paganuzzi</surname> <given-names>M.</given-names> </author><title>Carcinoembryonic antigen (CEA) in serum and bile of colorectal cancer patients with or without detectable liver metastases</title><source>Anticancer. Res.</source><year>1994</year><volume>14</volume><fpage>1409</fpage><lpage>1412</lpage>
<author><surname>Bell</surname> <given-names>H.</given-names> </author><author><surname>Orjasaeter</surname> <given-names>H.</given-names> </author><title>Five years&#8217; follow-up of patients with elevated carcinoembryonic antigen (CEA) and alcoholic liver disease, with special reference to mortality rate and development of malignancy</title><source>Hepatogastroenterology</source><year>1983</year><volume>30</volume><fpage>140</fpage><lpage>142</lpage>
<author><surname>Charalabopoulos</surname> <given-names>K.</given-names> </author><title>CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers</title><source>Med. Oncol.</source><year>2007</year><volume>24</volume><fpage>219</fpage><lpage>225</lpage>
<author><surname>Loewenstein</surname> <given-names>M.S.</given-names> </author><author><surname>Zamcheck</surname> <given-names>N.</given-names> </author><title>Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states</title><source>Cancer</source><year>1978</year><volume>42</volume><fpage>1412</fpage><lpage>1418</lpage>
<author><surname>Ladenson</surname> <given-names>J.H.</given-names> </author><author><surname>McDonald</surname> <given-names>J.M.</given-names> </author><author><surname>Landt</surname> <given-names>M.</given-names> </author><author><surname>Schwartz</surname> <given-names>M.K.</given-names> </author><title>(Washington University Case Conference). Colorectal carcinoma and carcinoembryonic antigen (CEA)</title><source>Clin. Chem.</source><year>1980</year><volume>26</volume><fpage>1213</fpage><lpage>1220</lpage>
<author><surname>Wang</surname> <given-names>J.Y.</given-names> </author><author><surname>Tang</surname> <given-names>R.</given-names> </author><author><surname>Chiang</surname> <given-names>J.M.</given-names> </author><title>Value of carcinoembryonic antigen in the management of colorectal cancer</title><source>Dis. Colon. Rectum.</source><year>1994</year><volume>37</volume><fpage>272</fpage><lpage>277</lpage>
<author><surname>Wang</surname> <given-names>W.S.</given-names> </author><title>Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience</title><source>Jpn. J. Clin. Oncol.</source><year>2000</year><volume>30</volume><fpage>12</fpage><lpage>16</lpage>
<author><surname>Okholm</surname> <given-names>M.</given-names> </author><author><surname>Iversen</surname> <given-names>L.H.</given-names> </author><author><surname>Thorlacius-Ussing</surname> <given-names>O.</given-names> </author><author><surname>Ejlersen</surname> <given-names>E.</given-names> </author><author><surname>Boesby</surname> <given-names>S.</given-names> </author><title>Fibrin and fibrinogen degradation products in plasma of patients with colorectal adenocarcinoma</title><source>Dis. Colon. Rectum.</source><year>1996</year><volume>39</volume><fpage>1102</fpage><lpage>1106</lpage>
<author><surname>Hatton</surname> <given-names>M.W.</given-names> </author><title>Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity</title><source>J. Lab. Clin. Med.</source><year>2004</year><volume>143</volume><fpage>241</fpage><lpage>254</lpage>
<author><surname>Hatton</surname> <given-names>M.W.</given-names> </author><title>Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors</title><source>J. Lab. Clin. Med.</source><year>2006</year><volume>147</volume><fpage>27</fpage><lpage>35</lpage>
<author><surname>Baker</surname> <given-names>E.A.</given-names> </author><author><surname>Bergin</surname> <given-names>F.G.</given-names> </author><author><surname>Leaper</surname> <given-names>D.J.</given-names> </author><title>Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression</title><source>Mol. Pathol.</source><year>2000</year><volume>53</volume><fpage>307</fpage><lpage>312</lpage>
<author><surname>Cohen</surname> <given-names>R.L.</given-names> </author><title>Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells</title><source>Blood</source><year>1991</year><volume>78</volume><fpage>479</fpage><lpage>487</lpage>
<author><surname>Stephens</surname> <given-names>R.W.</given-names> </author><title>Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis</title><source>J. Natl. Cancer Inst.</source><year>1999</year><volume>91</volume><fpage>869</fpage><lpage>874</lpage>
<author><surname>Nakasaki</surname> <given-names>T.</given-names> </author><title>Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer</title><source>Am. J. Hematol.</source><year>2002</year><volume>69</volume><fpage>247</fpage><lpage>254</lpage>
<author><surname>Seto</surname> <given-names>S.</given-names> </author><title>Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis</title><source>Cancer</source><year>2000</year><volume>88</volume><fpage>295</fpage><lpage>301</lpage>
<author><surname>Shigemori</surname> <given-names>C.</given-names> </author><title>Tissue factor expression and metastatic potential of colorectal cancer</title><source>Thromb. Haemost.</source><year>1998</year><volume>80</volume><fpage>894</fpage><lpage>898</lpage>
<author><surname>Versteeg</surname> <given-names>H.H.</given-names> </author><author><surname>Spek</surname> <given-names>C.A.</given-names> </author><author><surname>Peppelenbosch</surname> <given-names>M.P.</given-names> </author><author><surname>Richel</surname> <given-names>D.J.</given-names> </author><title>Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways</title><source>Mol. Med.</source><year>2004</year><volume>10</volume><fpage>6</fpage><lpage>11</lpage>
<author><surname>Nguyen</surname> <given-names>Q.D.</given-names> </author><title>Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment</title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>8240</fpage><lpage>8251</lpage>
<author><surname>Pepe</surname> <given-names>M.</given-names> </author><title>The Statistical Evaluation of Medical Tests for Classification and Prediction</title><source>Oxford Statistical Science Series 31</source><year>2003</year><other>New York</other><publisher>Oxford University Press</publisher>
<author><surname>Schaffrath</surname> <given-names>M.</given-names> </author><title>Ovarian Carcinoma: Clinical Validity by Simultaneous Determination of Fibrin Degradation Products with the DR-70&#8482; Immunoassay and CA-125</title><source>German J. Obstetrics and Gynocology</source><year>2006</year><volume>66</volume><fpage>68</fpage><lpage>75</lpage>
<author><surname>Li</surname> <given-names>X.</given-names> </author><author><surname>Qiao</surname> <given-names>Z.</given-names> </author><author><surname>Long</surname> <given-names>X.</given-names> </author><author><surname>Wei</surname> <given-names>J.</given-names> </author><author><surname>Cheng</surname> <given-names>Y.</given-names> </author><title>Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue</title><source>Br. J. Oral. Maxillofac. Surg.</source><year>2005</year><volume>43</volume><fpage>513</fpage><lpage>515</lpage>
<author><surname>Kerber</surname> <given-names>A.</given-names> </author><title>The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study</title><source>Aliment Pharmacol. Ther.</source><year>2004</year><volume>20</volume><fpage>983</fpage><lpage>987</lpage>
<author><surname>Wu</surname> <given-names>D.</given-names> </author><title>Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection</title><source>J. Immunoassay</source><year>1998</year><volume>19</volume><fpage>63</fpage><lpage>72</lpage>
<author><surname>Ding</surname> <given-names>L.</given-names> </author><author><surname>Ping</surname> <given-names>S.</given-names> </author><author><surname>Jingmei</surname> <given-names>Y.</given-names> </author><title>Application of tumor marker of DR-70&#174; in the diagnosis of malignant tumors</title><source>Chongqing Med. J.</source><year>1999</year><volume>28</volume><fpage>1</fpage><lpage>3</lpage>
<author><surname>Wu</surname> <given-names>D.F.</given-names> </author><title>Sensitivity &amp; Specificity of DR-70 Lung Cancer Immunoassay</title><source>Analytical Letters</source><year>1999</year><volume>32</volume><fpage>1351</fpage><lpage>1362</lpage>
<author><surname>Aliustaoglu</surname> <given-names>M.</given-names> </author><title>D-dimer-can it be a marker for malignant gastric lesions?</title><source>Acta. Oncol.</source><year>2004</year><volume>43</volume><fpage>770</fpage><lpage>771</lpage>
<author><surname>Rucker</surname> <given-names>P.</given-names> </author><author><surname>Antonio</surname> <given-names>S.M.</given-names> </author><author><surname>Braden</surname> <given-names>B.</given-names> </author><title>Elevated Fibrinogen-Fibrin Degradation Products (FDP) in Serum of Colorectal Cancer Patients</title><source>Analytical Letters</source><year>2004</year><volume>37</volume><fpage>2965</fpage><lpage>2976</lpage>
<author><surname>Lee</surname> <given-names>K.-H.</given-names> </author><author><surname>Cho</surname> <given-names>D.</given-names> </author><author><surname>Kim</surname> <given-names>K.-M.</given-names> </author><author><surname>Kim</surname> <given-names>S.-M.</given-names> </author><author><surname>Lee</surname> <given-names>D.-J.</given-names> </author><title>Meaning of the DR-70&#8482; Immunoassay for Patients with the Malignant Tumor</title><source>Immune Network</source><year>2006</year><volume>6</volume><fpage>43</fpage><lpage>51</lpage>
<author><surname>Xu</surname> <given-names>G.</given-names> </author><author><surname>Zhang</surname> <given-names>Y.L.</given-names> </author><author><surname>Huang</surname> <given-names>W.</given-names> </author><title>Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients</title><source>World J. Gastroenterol.</source><year>2004</year><volume>10</volume><fpage>922</fpage><lpage>923</lpage>
<author><surname>Oya</surname> <given-names>M.</given-names> </author><author><surname>Akiyama</surname> <given-names>Y.</given-names> </author><author><surname>Yanagida</surname> <given-names>T.</given-names> </author><author><surname>Akao</surname> <given-names>S.</given-names> </author><author><surname>Ishikawa</surname> <given-names>H.</given-names> </author><title>Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker</title><source>Surg. Today</source><year>1998</year><volume>28</volume><fpage>373</fpage><lpage>378</lpage>
<author><surname>Dirix</surname> <given-names>L.Y.</given-names> </author><title>Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer</title><source>Br. J. Cancer</source><year>2002</year><volume>86</volume><fpage>389</fpage><lpage>395</lpage>
<author><surname>Lengyel</surname> <given-names>E.</given-names> </author><title>Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade</title><source>Oncogene</source><year>1997</year><volume>14</volume><fpage>2563</fpage><lpage>2573</lpage>
<author><surname>De Sousa</surname> <given-names>L.P.</given-names> </author><title>Plasminogen/plasmin regulates c-fos and egr-1 expression via the MEK/ERK pathway</title><source>Biochem. Biophys. Res. Commun.</source><year>2005</year><volume>329</volume><fpage>237</fpage><lpage>245</lpage>
<author><surname>Dvorak</surname> <given-names>H.F.</given-names> </author><title>Thrombosis and cancer</title><source>Hum. Pathol.</source><year>1987</year><volume>18</volume><fpage>275</fpage><lpage>284</lpage>
<author><surname>Esumi</surname> <given-names>N.</given-names> </author><author><surname>Fan</surname> <given-names>D.</given-names> </author><author><surname>Fidler</surname> <given-names>I.J.</given-names> </author><title>Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor</title><source>Cancer Res.</source><year>1991</year><volume>51</volume><fpage>4549</fpage><lpage>4556</lpage>
<author><surname>Saksela</surname> <given-names>O.</given-names> </author><author><surname>Rifkin</surname> <given-names>D.B.</given-names> </author><title>Cell-associated plasminogen activation: regulation and physiological functions</title><source>Annu. Rev. Cell. Biol.</source><year>1988</year><volume>4</volume><fpage>93</fpage><lpage>126</lpage>
<author><surname>Schmitt</surname> <given-names>M.</given-names> </author><title>Tumor-associated urokinase-type plasminogen activator: biological and clinical significance</title><source>Biol. Chem. Hoppe Seyler</source><year>1992</year><volume>373</volume><fpage>611</fpage><lpage>622</lpage>
<author><surname>Dvorak</surname> <given-names>H.F.</given-names> </author><title>Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing</title><source>Lab. Invest.</source><year>1987</year><volume>57</volume><fpage>673</fpage><lpage>686</lpage>
<author><surname>Thompson</surname> <given-names>W.D.</given-names> </author><title>Angiogenic activity of fibrin degradation products is located in fibrin fragment E</title><source>J. Pathol.</source><year>1992</year><volume>168</volume><fpage>47</fpage><lpage>53</lpage>
<author><surname>Ruf</surname> <given-names>W.</given-names> </author><title>Diverse functions of protease receptor tissue factor in inflammation and metastasis</title><source>Immunol. Res.</source><year>2000</year><volume>21</volume><fpage>289</fpage><lpage>292</lpage>
<author><surname>Desrosiers</surname> <given-names>R.R.</given-names> </author><author><surname>Cusson</surname> <given-names>M.H.</given-names> </author><author><surname>Turcotte</surname> <given-names>S.</given-names> </author><author><surname>Beliveau</surname> <given-names>R.</given-names> </author><title>Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration</title><source>Int. J. Cancer</source><year>2005</year><volume>114</volume><fpage>702</fpage><lpage>712</lpage>
<author><surname>Dvorak</surname> <given-names>H.F.</given-names> </author><title>Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation</title><source>Ann. N. Y. Acad. Sci.</source><year>1992</year><volume>667</volume><fpage>101</fpage><lpage>111</lpage>
<author><surname>Gasic</surname> <given-names>G.J.</given-names> </author><title>Role of plasma, platelets, and endothelial cells in tumor metastasis</title><source>Cancer Metastasis Rev.</source><year>1984</year><volume>3</volume><fpage>99</fpage><lpage>114</lpage>
<author><surname>Yan</surname> <given-names>L.</given-names> </author><author><surname>Kumagai</surname> <given-names>S.G.</given-names> </author><author><surname>McGuire</surname> <given-names>M.H.</given-names> </author><author><surname>Yee</surname> <given-names>J.A.</given-names> </author><title>Protease activity and invasion of matrigel by the osteosarcoma-derived OSPR cell line</title><source>Biochem. Soc. Trans.</source><year>1994</year><volume>22</volume><fpage>18S</fpage>
<author><surname>Matsuyama</surname> <given-names>W.</given-names> </author><title>Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer</title><source>Chest</source><year>2000</year><volume>118</volume><fpage>948</fpage><lpage>951</lpage>
<author><surname>Kim</surname> <given-names>H.K.</given-names> </author><title>Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis</title><source>Blood Coagul Fibrinolysis</source><year>2004</year><volume>15</volume><fpage>9</fpage><lpage>13</lpage>
<author><surname>Oya</surname> <given-names>M.</given-names> </author><author><surname>Akiyama</surname> <given-names>Y.</given-names> </author><author><surname>Okuyama</surname> <given-names>T.</given-names> </author><author><surname>Ishikawa</surname> <given-names>H.</given-names> </author><title>High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer</title><source>Jpn. J. Clin. Oncol.</source><year>2001</year><volume>31</volume><fpage>388</fpage><lpage>394</lpage>
<author><surname>Blackwell</surname> <given-names>K.</given-names> </author><title>Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status</title><source>J. Clin. Oncol.</source><year>2000</year><volume>18</volume><fpage>600</fpage><lpage>608</lpage>
<author><surname>Tomimaru</surname> <given-names>Y.</given-names> </author><title>Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer</title><source>J. Am. Coll. Surg.</source><year>2006</year><volume>202</volume><fpage>139</fpage><lpage>145</lpage>
<author><surname>Blackwell</surname> <given-names>K.</given-names> </author><title>Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma</title><source>Cancer</source><year>2004</year><volume>101</volume><fpage>77</fpage><lpage>82</lpage>
<author><surname>Unsal</surname> <given-names>E.</given-names> </author><author><surname>Atalay</surname> <given-names>F.</given-names> </author><author><surname>Atikcan</surname> <given-names>S.</given-names> </author><author><surname>Yilmaz</surname> <given-names>A.</given-names> </author><title>Prognostic significance of hemostatic parameters in patients with lung cancer</title><source>Respir. Med.</source><year>2004</year><volume>98</volume><fpage>93</fpage><lpage>98</lpage>
<author><surname>Buccheri</surname> <given-names>G.</given-names> </author><author><surname>Torchio</surname> <given-names>P.</given-names> </author><author><surname>Ferrigno</surname> <given-names>D.</given-names> </author><title>Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance</title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>3044</fpage><lpage>3052</lpage>
<author><surname>Blackwell</surname> <given-names>K.L.</given-names> </author><title>HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors</title><source>Clin. Cancer Res.</source><year>2004</year><volume>10</volume><fpage>4083</fpage><lpage>4088</lpage>
<author><surname>Pavey</surname> <given-names>S.J.</given-names> </author><author><surname>Hawson</surname> <given-names>G.A.</given-names> </author><author><surname>Marsh</surname> <given-names>N.A.</given-names> </author><title>Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma</title><source>Blood Coagul Fibrinolysis</source><year>2001</year><volume>12</volume><fpage>51</fpage><lpage>58</lpage>
<author><surname>Hron</surname> <given-names>G.</given-names> </author><title>Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer</title><source>Thromb Haemost</source><year>2007</year><volume>97</volume><fpage>119</fpage><lpage>123</lpage>